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Introduction 
The significant advances achieved in the field of liver transplantation have led to 
an increased demand for organs, and created a wide gap between organ availabil-
ity and supply [1, 2J. As of 3 January 1996, there were 44025 patients on the Uni-
ted Network for Organ Sharing (UNOS) waiting list (the agency that coordinates 
organ allocation in the United States), up from 13115 on 31 December 1987, an 
increase of 335 %. Of these, 5715 awaited liver transplantation, up from 449 in 
1987 (ll-fold increase). The supply of organ donors, on the other hand, under-
went a marginal increase between 1988 and 1990 (from 4085 to 4514), and has 
remained relatively stable (4531 in 1991, 4521 in 1992, 4849 in 1993, and 4891 in 
1994) thereafter. A wider availability of organs for transplantation would allow 
an expansion [3, 41 rather than a contraction of the indications for transplanta-
tion, and at the same time a relaxation of the patient selection criteria [5-71. All 
these facts clearly justify the renewed interest in xenotransplantation observed in 
the last decade [8, 91. 
The first three attempts at whole organ xenotransplantation were made in 
France and Germany between January and April 1906, using a pig, a goat, and 
. a macaque as kidney donors [10, 111. None of these kidneys functioned because 
of almost immediate vascular thrombosis, and the human recipients died in less 
than 3 days. In a further attempt in 1923 by Neuhof [ll], a lamb was used as a 
kidney donor, and the patient died 9 days later. On 16 February 1963, Hitchcock 
transplanted the kidney of a baboon into a 65-year-old woman. The organ func-
tioned for 4 days before its artery clotted [131. A few months later, on 8 October 
1963, Reemtsma of Tulane University used a rhesus monkey as kidney donor for a 
human recipient, who survived 12 days. Reemtsma tried again with a series of six 
consecutive chimpanzee kidney grafts [141, one of which functioned for 270 days. 
In December 1963 and January 1964, six patients received baboon kidneys at 
the University of Colorado in Denver [151. Each of these kidneys functioned 
immediately and sustained a dialysis-free life for 10-60 days. The patients were 
treated with high doses of azathioprine and prednisone; four of them died of sep-
sis, while rejection was mainly responsible for the other two deaths. However, the 
pathology of the rejection was not qualitatively different from that observed in 
allografts [161. 
In fact, although the pathology of the rejection process was not well under-
stood during the early era of xenotransplantation, the descriptions of the rejected 
xenografted kidneys, from both baboons and chimpanzees, are consistent with 
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the pathophysiology of xenograft rejection as we describe it today. Lymphocyto-
toxic antibodies as a cause for antibody-mediated rejection of allografts were 
actually not recognized until 1965 [17], In the Denver baboon-to-human kidney 
xenotransplant series mentioned above, heterospecific antibodies could be 
detected bound to the kidney xenografts [15, 16]. Summarizing that experience, 
Dr. Kendrick Porter concluded: 
In the resulting [heterograft] rejection process, cellular infiltration and peri-
tubular capillary destruction are prominent early pathologic features, but by 
nine days the vasculonecrotic element is marked. There is circumstantial evi-
dence to suggest that, whereas the peritubular capillary damage is mediated by 
cell-bound antibody, the fibrinoid necrotic vascular lesions are caused by cir-
culating antibody. 
Porter also noted that the rejected xenografts showed variability in the histol-
ogy, from total infarction, cellular infiltrates, interstitial edema and tubular 
necrosis, to only intimal hypertrophy. The antibody component of rejection 
has been the central issue of xenotransplantation since that time. 
A pig kidney and a pig heart, transplanted in the 1960S by Kuss [18] and Ross 
[19], respectively, were hyperacutely rejected in a matter of minutes, demonstrat-
ing that the pig was not, and will not be, an easy donor for a human recipient. 
In 1968. the guidelines for defining brain death were published in the Journal 
of the American Medical Association [20 J. Almost overnight, the availability of 
brain-dead, heart-beating cadaver donors eliminated the need to continue the 
quest for nonhuman donor organs. Widespread access to dialysis and United 
States government financing of the end-stage renal disease program allowed 
patients with kidney failure to live and wait for kidney transplantation, whereas 
previously kidney transplantation was the only alternative to death. Interest in 
xenotransplantation of kidneys gave way to pretransplant management with dia-
lysis, and more timely transplantation with optimally functioning human kidney 
allografts. However, in the following two decades, the success achieved with allo-
transplantation triggered a new organ shortage crisis, highlighted by the increas-
ing number of patients dying while waiting for a human organ. This is particu-
larly disturbing in certain candidate populations. such as neonates and small 
children, where donor scarcity is even more Severe. Such was the rationale for 
the only attempt at human xenotransplantation in the cyclosporine era, when 
the shortage of neonatal hearts induced Bailey· and coworkers [21] to use a 
baboon heart in a 2.2-kg neonate recipient in 1984. In spite of the cyclosporine, 
steroid, azathioprine, and antithymocyte globulin treatment, immunopathological 
events similar to the ones observed by Porter [16 J 20 years before brought the 
baboon heart to irreversible failure within 3 weeks. No further attempts were 
made for almost a decade, until three human liver xenotransplantations, using 
two baboons and one pig, were performed in 1992 and 1993 [22-24). The descrip-
tion of the two baboon-to-human liver xenotransplantations. and the principles 
learned with this experience, are the subject of this chapter. 
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Work in the Laboratory and the Consensus Process 
In 1969, Sir Peter Medawar (25J stated: 
A new solution is therefore called for: the use of heterografts - that is to say, 
of grafts transplanted from lower animals into man. Of the use of heterografts 
I can say only this: that in the laboratory we are achieving greater success with 
grafts between species today than we achieved with grafts within 15 years ago. 
We shall solve the problem by using heterografts one day if we try hard 
enough, and maybe in less than 15 years. 
However, the laboratory work performed at different institutions in the follow-
ing 15-20 years did not bring results that could encourage further clinical trials. 
In May 1992, a study performed in Pittsburgh by Murase et aI. [26), using a 
hamster-to-rat xenotransplant model, was discussed at the meeting of the Amer-
ican Society of Transplant Surgeons in Chicago. Murase's work clearly showed 
that indefinite survival under tacrolimus (formerly FK506) was routinely achiev-
able if it was combined, for the first two post-transplant weeks, with either of two 
"antiproliferative" drugs: mycophenolate mofetil (an inhibitor of purine synth-
esis) or brequinar sodium (an inhibitor of pyrimidine synthesis). The use of 
cyclophosphamide, an alkylating agent with considerable B cell specificity [27, 
28), allowed similar consistent clironic survival after either heart or liver xeno-
transplantation. Particularly significant was the fact that a single large dose of 
cyclophosphamide, given 10 days before the xenotransplant, allowed success in 
almost 100 % of the animals with only daily administration of tacrolimus. This 
work, together with the previous experience with cyclophosphamide [29, 30) 
as an effective drug in clinical transplantation, justified its use in a clinical xeno-
graft trial. 
Pittsburgh Clinical Trial 
Planning 
Starting from this premise, in November 1991 the Pittsburgh Transplantation 
Institute notified the National Institute of Diabetes and Digestive and Kidney 
Diseases of the National Institutes of Health 0. Hoofnagle and P. Gordon), the 
Food and Drug Administration (R. Lieberman and G. Burke), and the Secretary 
of the Department of Health and Human Services (L. Sullivan) of the intention to 
proceed with the clinical liver xenotransplant project. Eight months were then 
needed to present the scientific documentation to the appropriate government 
agencies in the United States, the Institutional Review Board and the Ethics Com-
mittee of the University of Pittsburgh Medical Center, and members of the United 
States Congress with special interest in health care problems [31). Also, in March 
1992, a committee formed by six eminent European and American surgeons, 
coordinated by Keith Reemtsma of Columbia University, was brought together 
to hear the opinions of other experts before sanctioning the first clinical baboon 
liver xenotransplant. 
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After making several modifications to the initial protocol, on the basis of sug-
gestions made by the various experts consulted, the first xenotransplant was per. 
formed on 28 June 1992, and the second on 10 January 1993· During the long 
interval between the first and the second, and despite authorization to perform 
four consecutive liver xenotransplants [32), it was chosen to bring together the 
same group of experts previously consulted, this time at the New York Academy 
of Medicine, so that they could analyze the results obtained in the first xeno-
transplant. On this occasion, the Pittsburgh Transplantation Institute was advised 
to continue the clinical trial. 
The protocol for this human trial (approved by the Institutional Review Board 
of the University of Pittsburgh Medical Center [32) allowed baboon-to-human 
liver transplantation for the treatment of end-stage cirrhosis related to chronic 
active hepatitis B virus. In many areas of the world, infection with hepatitis B 
virus is endemic. Over 250 million people are affected by this disease worldwide 
(33), and it is also the most common cause of advanced liver disease and hepa-
tocellular carcinoma. Recurrence of infection after liver transplantation is high in 
this patient population, especially in the subset with positive viral replication 
markers (e.g., hepatitis B "e" antigen and/or hepatitis B DNA positivity) [J4, 
35). In many institutions this disease is considered a contraindication for liver 
allotransplantation. Because the baboon liver is thought to be resistant to the 
development of chronic active hepatitis B [22), the principal benefit to the 
patients enrolled in this trial was the possibility that the xenotransplanted 
liver would not be reinfected by the viral disease. The transplant was therefore 
planned as a permanent replacement for the failing human liver. 
Choice of Donor Species 
Nonhuman primates. by sharing many physiologic and genetic characteristics 
with humans, seemed to qualify as donors for this attempt. Primates are com-
prised of two suborders. Prosimii and Anthropoidea. Prosimian primates resem-
ble squirrels or rats more than true monkeys. The Anthropoidea suborder can be 
further subdivided into families: New World mgnkeys, Old World monkeys, lesser 
apes. great apes. and man. From an investigational standpoint, the most fre-
quently used species are the Old World monke¥s. This family includes rhesus 
monkeys (Macaca muiata), cynomologus monkeys (Macaca jascicuiaris), and 
baboons (Papio cynocephalus, Papio sphinx, Papio gelada. and Papio hamadryas) 
[36). Great apes include the chimpanzee (Pan troglodytes) and gorilla (Gorilla 
gorilla). but are not used in great numbers for research because of their endan-
gered classification, although their genome and their size approximate those of 
humans more than lesser apes. 
The liver anatomy in all primates is similar, with a right and left lateral lobe 
placed dorsally and a single large ventral central lobe. The liver of the Macaca 
and Papio is notable for lobation, with four identifiable lobes. In the higher 
order of primates. the central lobe fuses with the right and left lateral lobes. 
The quadrate lobe is much narrower in non-human primates than in man. and 
the caudate lobe may fully encircle the inferior vena cava. The ligamentous 
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attachments are similar to those described in man. The portal venous system is 
essentially identical in the higher order of primates. The hepatic venous drainage 
is similar to man, with small short hepatic venous tributaries draining the right 
and central lobes, with two large hepatic venous branches, one right and one left. 
In all primates, the gallbladder lies closely attached to the right or central lobe. 
The gallbladder arterial supply is usually from a branch of the right hepatic 
artery. The common bile duct empties into the duodenum. 
The chimpanzee is most likely the best donor in biological terms, due to the 
very small genetic differences between this species and humans. However, their 
endangered status prevents their widespread use for scientific purposes. In the 
United States, only 25-50 chimpanzees may be used annually in biomedical 
research, including those used in acquired immunodeficiency syndrome (AIDS) 
research [37], and it is estimated that only 70 chimpanzees would be available 
worldwide as organ donors each year [38]. Therefore, it was decided that the 
donor in the Pittsburgh clinical trial would be the baboon, Papio cynocephalus. 
Donor Baboon Selection Criteria 
The baboons used as donors came from the Southwest Foundation for Research 
and Education, San Antonio, Texas, the same institution that supplied the 
baboons used in the previous kidney xenotransplant trial [15]. All the baboons 
used during donor selection were born in the United States [36]. 
Baboons have group A, B, and AB antigens weakly expressed in all cells, with 
group 0 baboons being extremely rare [39-41]. However, ABO incompatibility 
did not affect the results of previous clinical xenotransplant trial [15, 42]. An 
ABO match is desirable in a baboon-to-human xenotransplant, but its absence 
does not constitute an absolute contraindication. Both of our human recipients 
in this trial, blood group A and B, respectively, received livers from compatible 
histo-blood group donors. 
In addition to histo-blood group, donor selection criteria included a Iympho-
cytotoxic crossmatch, as well as a complete biochemical, viral and bacteriological 
evaluation of the animals [22]. In particular, infectious disease screening was 
performed at the Virus Reference Laboratory of the Southwest Foundation for 
Research and Education, San Antonio, Texas. All potential donors were screened 
for retroviruses (simian T lymphocytic virus, STLV; human T lymphocytic virus, 
HTLV; simian immunodeficiency virus, SlY; SRV-l; SRV-2; SRV-5; human immu-
nodeficiency virus-I, HIV-l; HIV-2; foamy virus), herpesviruses (SA-8; herpes 
simplex virus, HSV; B virus; rCMV, cytomegalovirus; human CMV, hCMV; 
Epstein-Barr virus, EBV; varicella-zoster virus, VZV), and hepatitis A (HAV), 
B (HBV), and C (HCV) viruses. In addition, the baboons were examined to 
exclude tuberculosis and toxoplasmosis, and routine cultures of blood and 
feces were performed [43]. 
Baboons are physically smaller than humans. The maximum weight of an adult 
male baboon is about 30-35 kg. However, a liver from a smaller donor can rapidly 
grow to accommodate the size of a larger recipient [44]. A ~umber of suitable 
donors were se!ected and quarantined before the xenotransplant. 
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(ase Reports 
Donor Procedure 
The donor operation was performed using the traditional technique described by 
our group [45, 461. The operations on the donor and the recipient were per-
formed simultaneously, in two different operating rooms. Cold ischemia times 
were 80 min in the first case and 231 min in the second. University of Wisconsin 
solution was used to pre;erve the organs, as is done in our routine clinical prac-
tice. 
Recipient Selection 
The first patient was a 35-year-old white male, who had undergone a splenectomy 
in 1989 following a motor vehicle accident. The patient was found to be HIV 
positive, but his CD4 lymphocyte count was normal, as were in vitro mitogen 
r~sponses. The second patient was a 62-year-old white male with no previous 
abdominal surgery. Both patients had end-stage liver disease secondary to 
chronic active hepatitis B. In both patients, the principal complications of the 
liver disease were poorly controlled edema, fatigue, ascites, encephalopathy, 
and gastrointestinal bleeding. 
Operative Technique 
The liver xenotransplants were performed using a modification of the standard 
method [47], described 33 years ago (48), and employing a venovenous bypass 
[49). The difference in diameter between the vessels of donor and recipient, 
and the small size of the donor's liver (600 cmJ and 450 cmJ in the first and sec-
ond cases, respectively) made it necessary to use the piggy-back method [50]. In 
both cases the right suprahepatic vein of the recipient was closed with a running 
suture, while the left and middle suprahepatic veins were used to perform the 
suprahepatic vena cava anastomosis. In the first patient, given the considerable 
size discrepancy between the recipient and donor portal veins, the latter was ana-
stomosed end-Io-end onto the recipient's left portal branch, and the right branch 
was closed with a running suture. In the second case, a smaller discrepancy 
made it possible to perform a normal end-to-end portal anastomosis. 
The donor's celiac axis was anastomosed end-to-end onto the recipient's com-
mon hepatic artery in the first case, and end-to-side onto the supraceliac recipi-
ent aorta (using a donor carotid artery interposition graft) in the second. In both 
cases, the liver reperfused uniformly and produced bile on the operating table. 
The biliary anastomosis was done using a choledochojejunostomy on a Roux 
loop. In the second case, a small (3.SF) diameter catheter was placed into the bili-
ary anastomosis and brought out through the abdominal wall (Fig. 1), in order to 
gain direct access to the bile duct to study its anatomy and take bile samples dur-
ing the postoperative period. 
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Fig. 1. Second liver xenograft 
(baboon-to-human) recipient. 
Cholangiogram performed on 
postoperative day 18 by 
injection through a percuta-
neous biliary catheter. This 
catheter was placed during the 
xenotransplant operation 
(10 January 1993) across the 
choledochojejunostomy and 
allowed study of the biliary 
anatomy as well as daily 
collection of bile samples after 
the xenotransplantation. 
(From [96]) 
Immunosuppressive Therapy 
The immunosuppressive protocol comprised four drugs: cyclophosphamide, 
tacrolimus, methylprednisolone, and prostaglandin E,. Cyclophosphamide was 
begun 2 days prior to the transplant, and administered for a total of 56 days in 
the first case and 10 days in the second, at a dosage varying between 0.07 and 
10.6 mg/kg per day. Tacrolimus, steroids, and prostaglandin were started on the 
day of the transplant, using the same protocol we follow in clinical liver allo-
transplantation. Detailed descriptions of the immunosuppressive drug dosing 
and blood levels obtained are shown in Figs 2 and 3. 
Postoperative (ourse 
The first patient was extubated 17 h after the operation, he was placed on an oral 
diet on the fifth post-transplant day, and lived for 70 days. He spent most of this 
time in a regular hospital ward and had an almost normal plasma bilirubin level 
for the majority of the 70 days that he survived. The second patient, who was 
much older, never regained consciousness, remained icteric, and survived for 
only 26 days. Figures 2 and 3 illustrate their postoperative courses. 'The alkaline 
phosphatase was always very high in the first patient [51] (Fig.2). while in the 
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second patient it was not as .:onspicuously high. although it was always above 
normal limits. 
The first patient underwent five liver biopsies. while the second had seven. 
Only the biopsy obtained from the first patient on the 12th postoperative day 
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showed signs ot" mild focal cellular rejection, while no evidence of acute cellular 
rejection (according to the criteria routinely used in liver allotransplantation), 
was detected in any of the other biopsies from either patient [22, 23.31. 521. How-
ever, direct immunofluorescence demonstrated the presence of endothelial depos-
its of immunoglobulins (IgG>lgA>IgM) and complement (particularly Clq) in 
both cases [53]. No evidence of HBV reinfection was detectable by immunoperox-
idase staining in the liver tissue at any time. Since the period of follow-up was 
short, no definitive conclusions can be reached regarding the possibility of long-
term resistance of the baboon liver to hepatitis B recurrence. However, the most 
sensitive assay using polymerase chain reaction (PCR) could not detect hepatitis 
B DNA in the transplanted livers [54). 
Macroscopically, considerable hepatic regeneration was noted in both cases, 
with a significant increase in the volume of the baboon organs. Computed tomo-
graphy (CT) was used to calculate the volume of the transplanted livers [551. Both 
livers showed an extremely rapid growth, as normally occurs when a human liver 
is transplanted into a recipient with a larger abdomen than the donor [44). Fig-
ures 4 and 5 show the CT performed on the two recipients on the 26th and 14th 
postoperative days, respectively. The first patient's liver grew from an initial 
volume of 600 cmJ to 1555 cmJ in 26 days. The second patient's liver grew from 
an initial volume of 450 cm) to 1741 cm3 in 14 days. An angiogram performed 
on postoperative day 59 in the first patient showed that the vasculature of the 
transplanted xenograft had scaled up appropriately, i.e., the architectural rela-
tionships were preserved as the liver increased in volume. 
Papio cynocephalus normally produces elevated levels of factor VII and low 
levels of factors IX and XI, as compared to humans. Coagulation profiles were 
measured in both recipients preoperatively and several times postoperatively. 
Our results [56] showed that the baboon's coagulation pattern was acquired by 
Fig.4. First liver xenograft 
{baboon-to-burnanl recipient. 
Abdominal computed tomo-
gtaph,. (CTI on postoperative 
day 26. The liver volume has 
increased to 1555 em', from an 
initial value of 600 em'. (From 
[96 1> 
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Fig.5. Second liver xenograft 
(baboon-lo-human) recipient. 
Abdominal computed tomo-
graphy (CT) on postoperative 
day 14. The liver volume has 
increased to 1741 em', from an 
initial value of 450 em'. (From 
[96]) 
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the patients after liver xenografting, but this did not affect their clotting ability. 
No adverse effects of the presence of baboon proteins, such as immune-mediated 
kidney injury, could be detected at any time. 
In both patients there was evidence of an adequately functioning liver mass, 
such as: (a) normalization of coagulation with normal prothrombin time; (b) cor-
rection of hyperammonemia, (c) normal arterial ketone body ratio (a reflection 
of hepatic energy stores) [57), and (d) clearance of serum lactate. However, both 
patients suffered from hypoalbuminemia and needed to receive frequent albumin 
infusion. The baboon liver did impact on the protein profile of both patients. 
Liver-specific proteins could be shown to be of baboon origin by serum protein 
electrophoresis (Fig. 6). Total complement levels were depleted for 1-2 weeks after 
liver xenotransplantation, similar to that reported in liver allotransplantation 
across a positive lymphocytotoxic crossmatch [9, 22, 23. 52. 53. 58J. 
The first patient went into renal failure on postoperative day 21, while the sec-
ond patient became anuric immediately after surgery. Both patients suffered a 
number of infectious complications. Many of the organisms involved were typical 
of the agents seen after allotransplantation, e.g., Staphylococcus, Candida, CMV, 
Enterococcus, and Aspergillus. In the first patient, both the recipient and donor 
were CMV positive. Attempts to determine the origin of the subsequent CMV 
infection to either human or baboon origin failed because of inability to culture 
the CMV from clinical samples in sufficient quantity to subtype. However, the 
susceptibility of both baboon and human CMV to ganciclovir makes the origin 
of this virus of lesser practical importance. 
The causes of death in both patients were multifactorial. In the first, a rise in 
both the alkaline phosphatase and total bilirubin prompted a percutaneous trans-
hepatic cholangiogram on the 61st post-transplant day. Within 1 h after the pro-
-- ..... _---
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Hum 
Pat 
Bab 
Fig. 6. First liver xenograft (baboon-to-human) recipient. Protein electrophoresis of normal 
human (Hum), baboon donor (Bab). and patient serum (Pat). (3. complement; Tf. transferrin. 
(From [22]) 
cedure, the patient became hypotensive, febrile, and coagulopathic. He was intu-
bated, stabilized, and his clinical condition improved significantly. A positive cul-
ture for Aspergillus jlavus was noted, and amphotericin treatment was started. 
On the last day of his life (post-transplant day 70), the patient was hemodynami-
cally stable and was being weaned from the ventilator. Early in the afternoon he 
suddenly deteriorated neurologically. and a CT scan of the head revealed a mas-
sive subarachnoid bleed. The autopsy showed. as cause of death, a subarachnoid 
hemorrhage due to angioinvasive aspergillosis. In this patient, two foci of asper-
gillosis were found in the lungs. with focal dissemination to the kidneys and 
brain. The intrahepatic bile ducts were slightly dilated. and numerous bile 
infarcts were detected. Although the patient was in renal failure. the kidneys 
were intact and there was no evidence of immune complex deposition. 
The second patient died on the 26th post-transplant day from complications 
from peritonitis. It is likely that the high doses of corticosteroids used to control 
early immunologic damage were responsible for poor tissue healing. leading to a 
leak from the enteric anastomosis. 
There were some differences in the immunologic circumstances between the 
two cases. As mentioned before, the first patient had a splenectomy in 1989 fol-
lowing a motorcycle accident. whereas the second patient still had his spleen. 
which was subsequently removed 4 days after the xenotransplant. 
The first patient was also HIV positive. Our center traditionally does not 
refuse transplantation to HIV-positive patients [59 J, but analysis of the immuno-
logical parameters obviously differs in the case of an allotransplant. Although 
this first xenotransplant patient was considered immunocompetent at the time 
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of the transplant and had no change in this state during his postoperative course 
[22], it is difficult to judge whether his condition provided a natural immunosup-
pression, and whether or not this represented an advantage. 
After completing the vascular anastomoses the second patient was given an 
infusion of bone marrow cells from the donor baboon (3XI08/kg body weight). 
This was aimed at increasing the natural tolerogenicity induced by the liver 
transplant [60]. It is believed the liver has certain advantages in immunological 
terms on account of the large number of dendritic cells it possesses. These cells 
abandon the transplanted organ and participate in a two-way cell traffic, which 
gives rise to microchimerism [61,62]. The autopsy on the first patient confirmed 
this expectation, since baboon DNA was found (using peR amplification of 
baboon-specific DNA) in the patient's heart, kidneys, lungs, and lymph nodes. 
All blood samples taken from. the second patient during the postoperative course 
showed the presence of xenogeneic baboon DNA. 
Analysis of the Two Cases and Strategies For Future Clinical 
Xenotransplantation 
The most disquieting fact in our baboon-to-human liver transplant experience 
was the disparity between the paucity of the histopathologic findings of rejection 
(which was very encouraging), and the discouraging functional deficiencies of 
these xenotransplants, which suggested incomplete control of xenograft rejection. 
The pathology of the transplanted baboon livers was compared to that of six 
baboon kidney xenografts transplanted in Denver in 1963 [15, 16]. These kidneys, 
as we mentioned before, functioned for 10-60 days. The key pathological finding 
was an occlusive endothelialitis of the graft vessels, presumably antibody 
mediated. The pathology of those kidneys removed in 1964 [16] showed distal 
ischemia, caused by the vascular injury, that appeared to be responsible for 
the patchy gangrene of the xenografts. In the two recent liver xenotransplants, 
polymorphonuclear leukocytes were seen in the sinusoids immediately after 
reperfusion, and biliary sludging was detected at the autopsy. Both the sludging 
and the appearance of polymorphonuc~ar leukocytes were compatible with a 
diagnosis of an aborted hyperacute (humoral) rejection. Complement studies 
were also consistent with this possibility, showing that total complement was 
depleted for most of the critical first 2 weeks. While the complement system 
was restored, irreversible damage to the graft may have been already done [9, 
22, 23, 53]. Although these baboon liver xenografts looked macroscopically nor-
mal, closer inspection showed a very fine microsteatosis, which was particularly 
obvious in the second patient. This may represent a sub-lethal immunological 
injury that precluded long-term success in both cases. 
We suspect that these livers were acutely damaged by an incomplete version of 
a form of rejection that was described in 1964 in ABO-incompatible kidneys [63, 
64], and seen later in kidney allografts transplanted across a positive Iymphocy-
totoxic crossmatch [17]. These were the first descriptions of hyperacute kidney 
rejection by preformed antigraft antibodies. A few years later. hyperacute rejec-
tion was defined in a more sophisticated way as a complement activation syn-
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drome, analogous to the Shwartzman and local Arthus reactions [65, 661. It was 
pointed out that. although hyperacute allograft rejection was usually associated 
with antigraft antibodies, this was not an absolute requirement - a heretical 
statement at that time. However, the distinction between hyperacute rejection 
with and without preformed antibodies is merely the difference between the clas-
sical pathway of complement activation, in which the first steps are antibody 
dependent, and the alternative pathway, which does not require an antibody trig-
ger or the participation of complement components C1, C2, and C4. These hyper-
acute rejection syndromes, with or without preformed antigraft antibodies, are 
not fundamentally different from those seen after xenotransplantation of organs 
between genetically diverse species [91. • 
Many methods of manipulating the xenograft recipient have been tried and 
retried since the 1960s, without any definite success. These methods include anti-
body suppression [671, antibody depletion [68-79]. inhibition of the complement 
cascade [80-851, and inhibition of the int1ammatory response [86, 871. Alteration 
of the xenograft before its implantation, mainly by blocking antibody binding 
sites with recipient F(ab'), immunoglobulin fragments [76, 88, 89), has also 
been unsuccessful. 
The introduction of the concept of systemic chimerism has heightened interest 
in designing strategies aimed to alter the cell composition of the graft. The crea-
tion of a transgenic pig, to be utilized as a source of organs for clinical xeno-
transplants, has already been started in a few laboratories [90,911. The scientists 
working on this project have embarked on a program to produce pigs transgenic 
for human regulators of complement activation (e.g., decay-accelerating factor, 
DAF; CD59; membrane cofactor protein, MCP). This is achieved by microinjec-
tion of human genomic DNA fragments into the pronuclei of fertilized porcine 
oocytes [92-941. However, only one of the components of the xenotransplant bar-
rier could be overcome by this strategy (namely, the complement cascade); there-
fore it is difficult to hope that a complete control of rejection will be achieved by 
this method alone. 
One other extremely fascinating possibility is the produc;tion of chimeric 
organs. Human-to-baboon bone marrow transplantation has already been per-
formed at the Pittsburgh Transplantation Institute laboratories, after conditioning 
with nonlethal irradiation [951. In this experilTlent, two baboons preconditioned 
with 7.4 Gy total lymphoid irradiation were given unaltered human bone marrow 
cells at the dose of 6 x 108 cells/kg body weight, without any subsequent treat-
ment. Donor DNA was found widely distributed' in the tissues of both animals 
when killed 18 months later. It is also interesting to note that graft-versus-host 
disease (GvHD) did not occur in either animal. As recently stated elsewhere 
[91, "it remains to be seen if incomplete or even full chimerism will change the 
image of baboon organs enough to make them viewed as allografts by humans." 
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